ARGX vs. QGEN: A Head-to-Head Stock Comparison
Updated onHere’s a clear look at ARGX and QGEN, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.
Company Overview
ARGX’s market capitalization of 33.18 billion USD is substantially larger than QGEN’s 10.47 billion USD, indicating a significant difference in their market valuations.
QGEN carries a higher beta at 0.67, indicating it’s more sensitive to market moves, while ARGX (beta: 0.04) exhibits greater stability.
ARGX trades as an American Depositary Receipt (ADR), offering U.S. investors a convenient way to access its foreign-listed shares. In contrast, QGEN is a standard domestic listing.
| Symbol | ARGX | QGEN |
|---|---|---|
| Company Name | argenx SE | Qiagen N.V. |
| Country | NL | NL |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Medical - Diagnostics & Research |
| CEO | Timothy Van Hauwermeiren EMBA, | Thierry Bernard |
| Price | 543.48 USD | 48.34 USD |
| Market Cap | 33.18 billion USD | 10.47 billion USD |
| Beta | 0.04 | 0.67 |
| Exchange | NASDAQ | NYSE |
| IPO Date | May 18, 2017 | June 28, 1996 |
| ADR | Yes | No |
Historical Performance
This chart compares the performance of ARGX and QGEN by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period.
Data is adjusted for dividends and splits.
Profitability
Return on Equity
ARGX
16.83%
Biotechnology Industry
- Max
- 72.39%
- Q3
- -6.30%
- Median
- -32.82%
- Q1
- -68.26%
- Min
- -147.61%
In the upper quartile for the Biotechnology industry, ARGX’s Return on Equity of 16.83% signals a highly effective use of shareholder capital to drive profitability compared to most of its peers.
QGEN
2.69%
Medical - Diagnostics & Research Industry
- Max
- 57.35%
- Q3
- 18.17%
- Median
- 2.69%
- Q1
- -16.72%
- Min
- -48.78%
QGEN’s Return on Equity of 2.69% is on par with the norm for the Medical - Diagnostics & Research industry, indicating its profitability relative to shareholder equity is typical for the sector.
Return on Invested Capital
ARGX
-118.38%
Biotechnology Industry
- Max
- 48.74%
- Q3
- -10.68%
- Median
- -31.65%
- Q1
- -52.92%
- Min
- -113.69%
ARGX has a negative Return on Invested Capital of -118.38%. This indicates that its operations are failing to generate a profit on the total capital invested, signaling significant inefficiency or value destruction.
QGEN
1.57%
Medical - Diagnostics & Research Industry
- Max
- 42.99%
- Q3
- 11.55%
- Median
- 3.02%
- Q1
- -11.49%
- Min
- -40.79%
QGEN’s Return on Invested Capital of 1.57% is in line with the norm for the Medical - Diagnostics & Research industry, reflecting a standard level of efficiency in generating profits from its capital base.
Net Profit Margin
ARGX
37.53%
Biotechnology Industry
- Max
- 87.75%
- Q3
- -5.05%
- Median
- -103.44%
- Q1
- -1,032.77%
- Min
- -2,366.07%
A Net Profit Margin of 37.53% places ARGX in the upper quartile for the Biotechnology industry, signifying strong profitability and more effective cost management than most of its peers.
QGEN
4.68%
Medical - Diagnostics & Research Industry
- Max
- 22.76%
- Q3
- 15.19%
- Median
- 1.64%
- Q1
- -22.25%
- Min
- -78.24%
QGEN’s Net Profit Margin of 4.68% is aligned with the median group of its peers in the Medical - Diagnostics & Research industry. This indicates its ability to convert revenue into profit is typical for the sector.
Operating Profit Margin
ARGX
-1.24%
Biotechnology Industry
- Max
- 87.75%
- Q3
- -3.28%
- Median
- -115.26%
- Q1
- -1,188.86%
- Min
- -2,943.30%
ARGX has a negative Operating Profit Margin of -1.24%. This signifies the company is unprofitable at the operational level, as its core business expenses exceed its revenue.
QGEN
5.90%
Medical - Diagnostics & Research Industry
- Max
- 36.06%
- Q3
- 20.26%
- Median
- 6.15%
- Q1
- -21.89%
- Min
- -82.21%
QGEN’s Operating Profit Margin of 5.90% is around the midpoint for the Medical - Diagnostics & Research industry, indicating that its efficiency in managing core business operations is typical for the sector.
Profitability at a Glance
| Symbol | ARGX | QGEN |
|---|---|---|
| Return on Equity (TTM) | 16.83% | 2.69% |
| Return on Assets (TTM) | 13.45% | 1.69% |
| Return on Invested Capital (TTM) | -118.38% | 1.57% |
| Net Profit Margin (TTM) | 37.53% | 4.68% |
| Operating Profit Margin (TTM) | -1.24% | 5.90% |
| Gross Profit Margin (TTM) | 46.33% | 50.01% |
Financial Strength
Current Ratio
ARGX
7.29
Biotechnology Industry
- Max
- 28.73
- Q3
- 13.97
- Median
- 6.31
- Q1
- 3.60
- Min
- 0.02
ARGX’s Current Ratio of 7.29 aligns with the median group of the Biotechnology industry, indicating that its short-term liquidity is in line with its sector peers.
QGEN
3.37
Medical - Diagnostics & Research Industry
- Max
- 6.91
- Q3
- 4.11
- Median
- 2.46
- Q1
- 1.44
- Min
- 0.73
QGEN’s Current Ratio of 3.37 aligns with the median group of the Medical - Diagnostics & Research industry, indicating that its short-term liquidity is in line with its sector peers.
Debt-to-Equity Ratio
ARGX
0.01
Biotechnology Industry
- Max
- 0.46
- Q3
- 0.22
- Median
- 0.06
- Q1
- 0.02
- Min
- 0.00
Falling into the lower quartile for the Biotechnology industry, ARGX’s Debt-to-Equity Ratio of 0.01 points to a conservative financing strategy. This results in lower financial risk but potentially limits strategic investments compared to more leveraged competitors.
QGEN
0.41
Medical - Diagnostics & Research Industry
- Max
- 1.10
- Q3
- 0.82
- Median
- 0.39
- Q1
- 0.21
- Min
- 0.01
QGEN’s Debt-to-Equity Ratio of 0.41 is typical for the Medical - Diagnostics & Research industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.
Interest Coverage Ratio
ARGX
-20.85
Biotechnology Industry
- Max
- 108.32
- Q3
- -0.55
- Median
- -8.49
- Q1
- -74.83
- Min
- -168.36
ARGX has a negative Interest Coverage Ratio of -20.85. This indicates that its earnings were insufficient to cover even its operational costs, let alone its interest payments, signaling significant financial distress.
QGEN
2.89
Medical - Diagnostics & Research Industry
- Max
- 37.07
- Q3
- 5.62
- Median
- 1.76
- Q1
- -38.78
- Min
- -57.46
QGEN’s Interest Coverage Ratio of 2.89 is positioned comfortably within the norm for the Medical - Diagnostics & Research industry, indicating a standard and healthy capacity to cover its interest payments.
Financial Strength at a Glance
| Symbol | ARGX | QGEN |
|---|---|---|
| Current Ratio (TTM) | 7.29 | 3.37 |
| Quick Ratio (TTM) | 6.68 | 2.83 |
| Debt-to-Equity Ratio (TTM) | 0.01 | 0.41 |
| Debt-to-Asset Ratio (TTM) | 0.01 | 0.25 |
| Net Debt-to-EBITDA Ratio (TTM) | -189.75 | 2.07 |
| Interest Coverage Ratio (TTM) | -20.85 | 2.89 |
Growth
The following charts compare key year-over-year (YoY) growth metrics for ARGX and QGEN. These metrics are based on the companies’ annual financial reports.
Revenue Growth
Earnings Per Share (EPS) Growth
Free Cash Flow Growth
Dividend
Dividend Yield
ARGX
0.00%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
ARGX currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.
QGEN
2.73%
Medical - Diagnostics & Research Industry
- Max
- 2.76%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
With a Dividend Yield of 2.73%, QGEN offers a more attractive income stream than most of its peers in the Medical - Diagnostics & Research industry, signaling a strong commitment to shareholder returns.
Dividend Payout Ratio
ARGX
0.00%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
ARGX has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.
QGEN
0.00%
Medical - Diagnostics & Research Industry
- Max
- 37.46%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
QGEN has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.
Dividend at a Glance
| Symbol | ARGX | QGEN |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 2.73% |
| Dividend Payout Ratio (TTM) | 0.00% | 0.00% |
Valuation
Price-to-Earnings Ratio
ARGX
48.48
Biotechnology Industry
- Max
- 78.44
- Q3
- 48.98
- Median
- 20.50
- Q1
- 12.64
- Min
- 2.14
ARGX’s P/E Ratio of 48.48 is within the middle range for the Biotechnology industry. This suggests its valuation is in line with the sector average, representing neither a significant premium nor a discount compared to its peers.
QGEN
112.69
Medical - Diagnostics & Research Industry
- Max
- 48.28
- Q3
- 44.64
- Median
- 29.13
- Q1
- 22.34
- Min
- 15.59
At 112.69, QGEN’s P/E Ratio is exceptionally high, exceeding the typical maximum for the Medical - Diagnostics & Research industry. This suggests the stock may be significantly overvalued compared to its peers and implies high market expectations that could be difficult to meet.
Forward P/E to Growth Ratio
ARGX
1.27
Biotechnology Industry
- Max
- 2.29
- Q3
- 1.10
- Median
- 0.49
- Q1
- 0.16
- Min
- 0.02
A Forward PEG Ratio of 1.27 places ARGX in the upper quartile for the Biotechnology industry. This suggests the stock is potentially expensive compared to its peers relative to its growth forecast, which may warrant caution.
QGEN
12.81
Medical - Diagnostics & Research Industry
- Max
- 4.18
- Q3
- 3.64
- Median
- 2.40
- Q1
- 0.57
- Min
- 0.04
QGEN’s Forward PEG Ratio of 12.81 is exceptionally high for the Medical - Diagnostics & Research industry. This suggests its stock price is very high relative to its expected earnings growth, signaling significant overvaluation risk.
Price-to-Sales Ratio
ARGX
15.66
Biotechnology Industry
- Max
- 110.90
- Q3
- 59.76
- Median
- 11.33
- Q1
- 4.45
- Min
- 0.17
ARGX’s P/S Ratio of 15.66 aligns with the market consensus for the Biotechnology industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.
QGEN
5.23
Medical - Diagnostics & Research Industry
- Max
- 12.53
- Q3
- 6.19
- Median
- 3.58
- Q1
- 1.95
- Min
- 0.58
QGEN’s P/S Ratio of 5.23 aligns with the market consensus for the Medical - Diagnostics & Research industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.
Price-to-Book Ratio
ARGX
7.35
Biotechnology Industry
- Max
- 15.78
- Q3
- 7.44
- Median
- 3.31
- Q1
- 1.58
- Min
- 0.31
The P/B Ratio is often not a primary valuation metric for the Biotechnology industry.
QGEN
3.10
Medical - Diagnostics & Research Industry
- Max
- 10.67
- Q3
- 5.74
- Median
- 2.95
- Q1
- 1.30
- Min
- 0.39
The P/B Ratio is often not a primary valuation metric for the Medical - Diagnostics & Research industry.
Valuation at a Glance
| Symbol | ARGX | QGEN |
|---|---|---|
| Price-to-Earnings Ratio (P/E, TTM) | 48.48 | 112.69 |
| Forward PEG Ratio (TTM) | 1.27 | 12.81 |
| Price-to-Sales Ratio (P/S, TTM) | 15.66 | 5.23 |
| Price-to-Book Ratio (P/B, TTM) | 7.35 | 3.10 |
| Price-to-Free Cash Flow Ratio (P/FCF, TTM) | -432.72 | 20.81 |
| EV-to-EBITDA (TTM) | 4329.99 | 30.20 |
| EV-to-Sales (TTM) | 15.00 | 5.61 |